Therapeutic vaccination for cancer: The potential value of mycobacterial products

International Journal of Pharmaceutical Medicine

Volumn 13, Issue 4, 1999, Pages 191-195

  Stanford, John L ^a   Stanford, C A ^a   Baban, B ^a   Grange, J M ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

BCG; Cancer; Coley toxins; Immunotherapy; Mycobacteria vaccae

Indexed keywords

BACTERIAL TOXIN; BCG VACCINE; CANCER VACCINE; DNA VACCINE; GAMMA INTERFERON; HEAT SHOCK PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; MYCOBACTERIUM VACCINE; RECOMBINANT CYTOKINE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR;

ARTICLE; BLADDER CANCER; CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG TOXICITY; HELPER CELL; HUMAN; IMMUNOMODULATION; INTRAVESICAL DRUG ADMINISTRATION; LUNG CANCER; MELANOMA; MYCOBACTERIUM VACCAE; PRIORITY JOURNAL; PROSTATE CANCER; TUBERCULOSIS;

EID: 0032822849     PISSN: 13649027     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Coley WB.The treatment of malignant tumors by repeated inoculations of erysipelas. Historical article reprinted in Clin Orthop 1991; 262:3-11.
2. Takeuchi S. A new look at the history of tumour immunotherapy - for its fruitful future through overcoming the widespread cynicism. Hum Cell 1996; 9:1-10 (In Japanese with English abstract).
3. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233:1318-1321.
4. Reynolds T. Cancer vaccine competition wide open as agents move rapidly into clinical arena. J Natl Cancer Inst 1999; 91:309-312.
5. Lukacs KV, Nakakes A, Atkins CJ, Lowrie DB, Colston MJ. In vivo gene therapy of malignant tumours with heat shock protein-65 gene. Gene Ther 1997; 4:346-350
6. Figlin RA. Renal cell carcinoma: management of advanced disease. J Urol 1999; 161:381-386.
7. Grange JM, Stanford JL, Rook GAW. Tuberculosis and cancer: parallels in host responses and therapeutic approaches? Lancet 1995; 345:1350-1352.
8. Starnes CO. Coley's toxins in perspective. Nature 1992; 357:11-12.
9. Grange JM, Stanford JL. BCG vaccination and cancer. Tubercle 1990; 71:61-64.
10. Fine PEM: Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346:1339-1345.
11. Mathe G, Florentin I, Olsson L, Bruley-Rosset M, Schulz J, Kiger N, Orbach-Arbouys S, Schwarzenberg L, Pouillart P, de Vassal F. Pharmacologic factors and manipulation of immunity systemic adjuvants in cancer therapy. Cancer Treat Rep 1978; 62:1613-1621.
12. Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norten BJ. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guérin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999; 161:1124-1127.
13. Hsueh EC, Gupta RK, Qi K, Morton DL. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998; 16:2913-2920.
14. Bothamley GH, Grange JM. The Koch phenomenon and delayed hypersensitivity: 1891-1991. Tubercle 1991; 72:7-11.
15. Lefford MJ. Delayed hypersensitivity and immunity in tuberculosis. Amer Rev Respir Dis 1975; 111:243-246.
16. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17:138-146.
17. Rook GAW. Tumours and Coley's toxins. Nature 1992; 357:545.
18. Hoon DS, Hayashi Y, Morisaki T, Foshag LJ, Morton DL. lnterleukin-4 plus tumor necrosis factor alpha augments the antigenicity of melanoma cells. Cancer Immunol Immunother 1993; 37:378-384.
19. Kaempfer R, Gerez L, Farbstein H, Madar L, Hirschman O, Nussinovich R, Shapiro A. Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J Clin Oncol 1996; 14:1778-1786.
20. Wittke F, Hoffmann R, Buer J, Dallmann I, Oevermann K, Sel S, Wandert T, Ganser A, Atzpodien J. Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br J Cancer 1999; 79:1182-1184.
21. O'Hara RJ, Greenman J, MacDonald AW, Gaskell KM, Topping KP, Duthie GS, Kerin MJ, Lee PW, Monson JR. Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production. Clin Cancer Res 1998; 4:1943-1948.
22. Jacobs N, Giannini SL, Doyen J, Baptista A, Moutschen M, Boniver J, Delvenne P. Inverse modulation of IL-10 and IL-12 in the blood of women with preneoplastic lesions of the uterine cervix. Clin Exp Immunol 1998; 111:219-224.
23. Baban B. The evuation of a heat-killed suspension of Mycobacterium vaccae as an immunomodulating agent in the treatment of cancer. PhD Thesis. University of London, 1998.
24. Wang CC, Rook GA. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunology 1998; 93:307-313.
25. Nye PM, Price JE, Revankar CR, Rook GA, Stanford JL.The demonstration of two types of suppressor mechanism in leprosy patients and their contacts by quadruple skin-testing with mycobacterial reagent mixtures. Lepr Rev 1983; 54:9-18.
26. Rook GAW. The immunogenicity of killed mycobacteria. Lepr Rev 1980; 51:295-301.
27. Maraveyas A, Baban B, Kennard D, Rook GAW, Westby M, Grange JM, Lydyard P, Stanford JL, Jones M, Selby P, Dalgleish AG. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood leucocytes. Ann Oncol 1999; 10:817-824.
28. Hrouda D, Baban B, Dunsmuir WD, Kirby RS, Dalgleish AG. Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). Br J Urol 1998; 8:568-573
29. Webb A, Al-Moundhri M, Souberbielle B, Norton A, Priest K, Ryan C, Mendes R, Ashley S, Smith IE, O'Brien MER. A randomised study of SRL 172 in patients with advanced lung cancer treated with chemotherapy. Br J cancer 1998; 78 Suppl. 2:4.
30. Chang AE, Shu S. Current status of adoptive immunotherapy of cancer. Crit Rev Oncol Hematol 1996; 22:213-228.
31. Hrouda D, Souberbielle BE, Kayaga J, Corbishley CM, Kirby RS, Dalgleish AG. Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer. J Urol 1998; 82:870-876.